Aktienanalyse zu Harvard Bioscience Inc (HBIO)HBIOHarvard Bioscience Inc

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Harvard Bioscience Inc is a good buy right now due to its recent performance and growth potential. The current price is $7.93, and the company reported a 30% increase over the last 20 days, indicating strong momentum. Additionally, the forward P/E ratio is 15.06, suggesting that the stock may be undervalued compared to future earnings expectations. However, the main risk is the negative net income of $2.9 million reported in the latest quarter, which could impact future profitability.

3 analysts cover HBIO: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 2.00.